In This Article
The short answer: Body weight and waist circumference are lagging indicators. The pathophysiology research on insulin resistance describes a chain that can start with rising fasting insulin years before glucose, weight, or waist size move enough to notice. This guide walks through that chain, the specific bloodwork markers tied to each step, and why a normal-weight person can still be metabolically at risk.
- Why Bloodwork Shifts First
- The Marker Sequence
- The Markers to Know
- The Normal-Weight Myth
- What to Do Next
- FAQ
- Key Takeaways
- References
Read key takeaways →
Why Bloodwork Can Shift Before the Scale Does
Gerald Reaven, in his 1988 Banting Lecture published in Diabetes, proposed that a cluster of problems long blamed on separate causes, including high triglycerides, low HDL cholesterol, high blood pressure, and elevated glucose, actually traced back to a single upstream driver: insulin resistance. He called it Syndrome X at the time; it is now generally known as metabolic syndrome. The core idea still holds up: several markers can move together long before any one of them is visibly abnormal on its own.
Ralph DeFronzo and Devjit Tripathy, in a 2009 review in Diabetes Care, made the timeline explicit. They argued that skeletal muscle insulin resistance, the reduced ability of muscle tissue to take up glucose in response to insulin, is typically evident decades before beta-cell failure and overt high blood sugar develop. The body compensates for early insulin resistance by secreting more insulin, which is why fasting insulin and calculated insulin resistance can rise while fasting glucose still reads normal.
The Compensation Window
Cells respond less to insulin
Muscle and liver tissue need more insulin than before to clear the same amount of glucose from the blood.
The pancreas compensates
Beta cells secrete more insulin to hold glucose steady. Fasting glucose can look normal for years during this stage.
Compensation starts to fail
Beta-cell output can no longer fully offset the resistance. Glucose and HbA1c begin drifting upward.
Chris Weyer and colleagues, in a 1999 longitudinal study in the Journal of Clinical Investigation, tracked Pima Indian adults as their glucose tolerance moved from normal to impaired to diabetic over roughly five years on average. The transition to impaired glucose tolerance came with a measurable decline in insulin-stimulated glucose disposal and a weakening insulin secretory response, changes that were underway before diabetes was diagnosable by a glucose test. Their data describes one studied population's progression rather than a fixed timeline for every person, but it supports the same point DeFronzo and Tripathy make: by the time glucose numbers move, the underlying resistance has usually been building for a while.
A Model for the Order Markers Tend to Drift In
No single study has proven a universal, fixed order that every person's bloodwork follows. What the research above supports is a general model, built from the compensation mechanism, that clinicians use to explain why some markers tend to move earlier than others. Treat this as a framework for what to watch, not a guarantee of your own sequence.
Earliest: fasting insulin and HOMA-IR
Rises as the pancreas compensates for reduced insulin sensitivity, often while every other panel value is still in range.
Next: triglycerides, HDL, and liver enzymes
Excess insulin signaling pushes the liver toward more fat production and storage, showing up as a rising triglyceride to HDL ratio and, later, elevated ALT.
Later: fasting glucose, HbA1c, weight, and waist
Once compensation can no longer keep up, glucose control and, often, visible weight or waist changes follow.
This ordering will not match every individual case. Genetics, muscle mass, ethnicity, and diet composition all shift how fast, and in what order, these markers move. Use it to decide which numbers to ask your doctor about, not to self-diagnose a stage.
The Specific Markers and What They Measure
A handful of common blood tests carry more early-warning signal for this pathway than glucose alone. None of them is a diagnosis by itself, and all of them are meant to be read as trends alongside a clinician, not interpreted from a single draw.
Fasting insulin and HOMA-IR
David Matthews and colleagues, in a 1985 paper in Diabetologia, introduced HOMA-IR, a calculation from fasting glucose and fasting insulin that estimates insulin resistance without more invasive testing. It is the marker most likely to move first because it directly reflects the compensation stage described above.
Triglyceride to HDL ratio
Thomas McLaughlin and colleagues, in a 2003 study in the Annals of Internal Medicine, found a fasting triglyceride to HDL cholesterol ratio of 3 or higher was a reliable surrogate for insulin resistance in overweight adults, tracking almost as closely with measured insulin sensitivity as fasting insulin itself.
ALT (a liver enzyme)
Naveed Sattar and colleagues, in a 2004 study in Diabetes following nearly 6,000 men, found that ALT rose progressively with the number of metabolic syndrome features present, and that men in the top quartile for ALT had a substantially higher hazard of developing new-onset diabetes over about five years, independent of classical risk factors.
Fasting glucose and HbA1c
The markers most people already get tested. Useful as a confirmation, but by the time they drift out of range the resistance behind them, per DeFronzo and Tripathy's (2009) review, has typically been present for years.
The Misconception: Normal Weight Means Metabolically Healthy
Misconception: a normal BMI rules out insulin resistance. Neil Ruderman and colleagues named this pattern in a 1981 paper in the American Journal of Clinical Nutrition, describing "metabolically obese, normal-weight" individuals who showed the hyperinsulinemia and metabolic disturbances typical of obesity despite falling within a normal weight range on standard tables.
Elizabeth Thomas and colleagues, in a 2012 imaging study in Obesity, gave this pattern a more visual name: TOFI, thin on the outside, fat on the inside. Using MRI and MR spectroscopy, they showed that some normal-weight adults carried a higher ratio of visceral to subcutaneous abdominal fat, along with more fat stored inside the liver and muscle tissue, the same ectopic fat pattern associated with insulin resistance in people with obesity. Scale weight and even BMI cannot see this distribution; it is a body composition and organ-fat pattern, not a body-weight one.
This is also why insulin resistance can show up in wearable data before a routine physical catches it. Elevated resting heart rate, blunted HRV, and glucose variability on a CGM can all reflect the same early metabolic strain that fasting insulin and the triglyceride to HDL ratio are picking up in bloodwork.
What to Do With This Pattern
Ask for the early markers, not just glucose
Fasting insulin, HOMA-IR, and a standard lipid panel (which gives you the triglyceride to HDL ratio) are inexpensive additions to a routine blood draw and catch this pathway earlier than fasting glucose alone.
Track trend, not a single draw
One elevated HOMA-IR reading can reflect a rough week of sleep or a recent illness. A rising trend across two or three annual panels is the signal worth acting on.
Do not rely on weight or waist alone to reassure yourself
Given the TOFI pattern Thomas and colleagues (2012) described, a stable scale weight is not proof that the underlying markers are stable too, particularly if daily activity has dropped or sleep and stress have gotten worse.
Address the drivers, not just the numbers
The interventions that improve insulin sensitivity, resistance training, aerobic activity, adequate sleep, and reducing ultra-processed carbohydrate intake, work on the mechanism itself rather than any single marker.
Frequently Asked Questions
Which blood marker moves first when metabolic health starts to decline?
The pathophysiology research points to fasting insulin and HOMA-IR as the earliest markers to shift, because they reflect the pancreas compensating for reduced insulin sensitivity before glucose itself is affected (DeFronzo and Tripathy, 2009). This is a general model from mechanism-based research, not a fixed sequence proven to hold for every individual.
Can I be insulin resistant with a completely normal weight?
Yes. Ruderman and colleagues (1981) first described "metabolically obese, normal-weight" individuals, and Thomas and colleagues' (2012) MRI research found some normal-weight adults carry a pattern of visceral and organ fat, sometimes called TOFI, associated with the same insulin resistance seen in obesity.
What does a triglyceride to HDL ratio actually tell me?
McLaughlin and colleagues (2003) found a fasting triglyceride to HDL cholesterol ratio of 3 or higher was a reliable surrogate marker for insulin resistance in overweight adults. It is calculated from a standard lipid panel, so you likely already have the numbers needed to check it.
Why would a liver enzyme like ALT matter for metabolic health?
Sattar and colleagues (2004) found ALT rose progressively with the number of metabolic syndrome features present and predicted new-onset diabetes independent of classical risk factors, in part because excess insulin signaling promotes fat storage in the liver.
How often should I retest these markers?
There is no single validated interval for this specific marker set. Most clinicians attach fasting insulin and a lipid panel to an annual physical; if a marker is trending the wrong way, your doctor may want to recheck sooner. Follow their guidance over any fixed schedule.
Does this mean fasting glucose and HbA1c are not useful?
No, they remain important confirmatory tests and are what most diagnostic criteria for prediabetes and diabetes are built on. The point of this article is that they tend to be later indicators in the pathway Reaven (1988) and DeFronzo and Tripathy (2009) describe, not that they should be skipped.
What to Remember
- →Reaven's (1988) insulin resistance model and DeFronzo and Tripathy's (2009) review both describe insulin resistance as a driver that can precede visible weight or glucose changes, sometimes by years.
- →A general model, not a proven fixed sequence, places fasting insulin and HOMA-IR as early movers, triglyceride to HDL ratio and ALT as mid-stage markers, and fasting glucose, HbA1c, weight, and waist as later indicators.
- →HOMA-IR (Matthews et al., 1985) and the triglyceride to HDL ratio (McLaughlin et al., 2003, using a cutpoint of 3 or higher) are calculable from routine, inexpensive lab work.
- →Elevated ALT predicted new-onset diabetes independently of classical risk factors in Sattar and colleagues' (2004) study of nearly 6,000 men.
- →Normal body weight does not rule out this pattern. Ruderman and colleagues (1981) and Thomas and colleagues' (2012) MRI research both describe normal-weight adults carrying insulin resistance and elevated visceral or organ fat.
- →Track these markers as a multi-year trend with a clinician, not as a single data point to self-diagnose from.
Related on Protocol
How to Interpret Fasting Insulin and HOMA-IR: Your Metabolic Baseline
A closer look at the earliest marker in this pattern and how to read it
What Insulin Resistance Looks Like in Your Wearable Data Before You Know You Have It
How resting heart rate, HRV, and glucose variability can flag the same pathway
How to Interpret Your Lipid Panel: LDL Particles, ApoB, and What Actually Matters
More on reading triglycerides and HDL alongside the rest of your lipid panel
Track the trends that move before the scale does
Protocol brings your bloodwork, resting heart rate, HRV, and sleep data into one place, so you can watch for early metabolic drift instead of waiting for a number to move.
Get started freeReferences
Key Researchers
- Gerald Reaven (Stanford University) Proposed insulin resistance as the common driver behind clustered metabolic abnormalities in his 1988 Banting Lecture, later known as metabolic syndrome.
- Ralph DeFronzo (University of Texas Health San Antonio) Co-author of the 2009 review describing skeletal muscle insulin resistance as evident decades before overt hyperglycemia.
- Neil Ruderman (Boston University) Coined the "metabolically obese, normal-weight" concept in 1981, the precursor to the modern TOFI pattern.
Key Studies
- Reaven (1988) Diabetes (Banting Lecture). Proposed insulin resistance as the shared mechanism behind high triglycerides, low HDL, high blood pressure, and elevated glucose.
- Matthews et al. (1985) Diabetologia. Introduced HOMA-IR, a calculation of insulin resistance from fasting glucose and fasting insulin.
- Weyer et al. (1999) Journal of Clinical Investigation. Longitudinal study of Pima Indian adults showing declining insulin sensitivity and secretion as glucose tolerance worsened over roughly five years.
- DeFronzo and Tripathy (2009) Diabetes Care. Review arguing skeletal muscle insulin resistance is the primary, early defect in type 2 diabetes, present long before beta-cell failure.
- McLaughlin et al. (2003) Annals of Internal Medicine. Found a triglyceride to HDL cholesterol ratio of 3 or higher was a reliable surrogate marker for insulin resistance in overweight adults.
- Sattar et al. (2004) Diabetes. Found elevated ALT predicted new-onset type 2 diabetes independently of classical risk factors in nearly 6,000 men.
- Ruderman et al. (1981) American Journal of Clinical Nutrition. Described "metabolically obese, normal-weight" individuals with hyperinsulinemia despite a normal body weight.
- Thomas et al. (2012) Obesity. MRI and MR spectroscopy study describing the TOFI (thin on the outside, fat on the inside) pattern of visceral and organ fat in normal-weight adults.
